CILA Therapeutics

CILA Therapeutics, founded in 2018 by Dr. Safia K. Rizvi, aims to help patients suffering from obstructive airway diseases. No effective treatments currently exist to improve breathing from mucus obstructions that prevent the efficacy of inhaled therapies. Overproduction of mucus or mucociliary clearance can lead to build up and the formation of mucus plugs that are difficult to clear, cause inflammation, and increase risk of infection, leading to irreversible damage and potentially respiratory failure. CILA’s purpose is to timely develop cost-effective treatments for pulmonary disease that not only alleviates breathing issues, but also protects the lungs and airways from progressive damage.

Jobs: